The tumor microenvironment (TME) in non-small cell lung cancer (NSCLC) is shaped by both immune infiltration and metabolic reprogramming, which together modulate therapeutic response. We applied Akoya’s PhenoCode^TM Discovery IO60 Panel, combined with a spike-in PhenoCode Metabolic Module, to spatially characterize immunometabolic interactions in FFPE NSCLC samples, including both adenocarcinoma and squamous cell carcinoma (SqCLC) subtypes.

AI-powered image analysis and spatially resolved cellular phenotyping were performed using Visiopharm®, enabling high-dimensional, quantitative assessment of cell types and their spatial relationships within the immunometabolic contexture.

Alyssa Whitley¹⁺, Daniel Winkowski, PhD²⁺, Yue Hou¹, Matthew Moore¹, Ritu Mihani, PhD¹, Regan Baird, PhD² and Katherine J. Hales, PhD²

1. Akoya Biosciences, a Quanterix Company, Marlborough, MA
2. Visiopharm Corp., Broomfield, CO.